July 16, 2018 08:35 AM EDT

Chasing Biogen, the Pliant crew banks a $62M round to fuel their shot at fibrosis targets

Amber Tong

South San Francisco-based Pliant Therapeutics has just closed a $62 million round to take their idiopathic pulmonary fibrosis drug to the clinic — the first of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Chasing Biogen, the Pliant crew banks a $62M round to fuel their shot at fibrosis targets

Amber Tong

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Here's what today's Fed rate cut means for biotech, pharma and venture capital

FDA cancels Applied Therapeutics adcomm, shares skyrocket 65%

All of 23andMe's independent board members resign over disagreements with CEO

You bet your life: After I was diagnosed with a rare cancer, I discovered how a small band of physician-scientists ...

With few efficacy details, Insilico claims a Phase 2a win in latest AI readout

Breaking down silos with a new quantitative approach to drug development

Chas­ing Bio­gen, the Pli­ant crew banks a $62M round to fu­el their shot at fi­bro­sis tar­gets

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Chasing Biogen, the Pliant crew banks a $62M round to fuel their shot at fibrosis targets